After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Disclaimer: neither I nor Ruwan Bandujeewa know of a Nandani Warusavithana. If such a person does exist, please note that ...